Assignee: Sunesis Pharmaceuticals, Inc.

Location: South San Francisco, CA
No. of patents: 21

Number	Title	Issue Date
8138202	Stable SNS-595 compositions and methods of preparation Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. ...	03/20/2012
8124773	1,8-naphthyridine compounds for the treatment of cancer Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the...	02/28/2012
8114887	Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved...	02/14/2012
7989468	Methods of using SNS-595 The present invention relates to SNS-595 and methods of treating cancer using the same. ...	08/02/2011
7968536	Heterocyclic compounds useful as RAF kinase inhibitors The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. ...	06/28/2011
7932257	Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: ...	04/26/2011
7767687	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: ...	08/03/2010
7601725	Thienopyrimidines useful as Aurora kinase inhibitors The present invention provides compounds having the formula: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and s...	10/13/2009
7314938	Modulators of cellular adhesion The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1	01/01/2008
7214487	Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates The present invention relates to methods for identifying compounds that modulate enzymatic activity by contacting covalently bonded PTP-extender complexes or modified covalently bonded PTP-extender complexes with ligand candidates. ...	05/08/2007
7202033	Identification of kinase inhibitors The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase. The inhibitors are identified by locking the target protein kinase in an inactive conformation, and using a coval...	04/10/2007
7132568	Aspartyl protease inhibitors The present invention provides compounds having formula (I): wherein R′, R0, R1, X1, R2, R3, R3′, X2, X3 and R4 ...	11/07/2006
7122687	Process for the production of an immunosuppressant In one aspect, the present invention provides a process for producing a sodium salt of an immunosupressant of Formula I ...	10/17/2006
7115654	Caspase-1 inhibitors and methods for their use The invention provides compounds of Formula I and derivatives thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of treatment utilizing such compounds and compositions:	10/03/2006
7115652	Aspartyl protease inhibitors The present invention provides compounds having the formula: wherein R1, R′, R2, R3, R3′, R4, X1, X2 and X3 are as defin...	10/03/2006
6998233	Methods for ligand discovery The present invention provides novel methods for ligand discovery. The inventive methods rely on a process termed “tethering” where potential ligands are covalently bonded or “tethered” to a target and subsequently identified. ...	02/14/2006
6919178	Extended tethering approach for rapid identification of ligands The invention concerns a method for rapid identification and characterization of binding partners for a target molecule, and for providing binding partners with improved binding affinity. More specifically, the invention concerns an improved tethering method for the...	07/19/2005
6878743	Small molecule inhibitors of caspases The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein A, B, D, E, G, J, n, and R1 are as described generally and i...	04/12/2005
6811966	Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules The present invention is directed to novel methods for rapidly and unambiguously identifying small organic molecule ligands for binding to biological target molecules. Small organic molecule ligands identified according to the methods of the present invention may fi...	11/02/2004
6806279	Small-molecule inhibitors of interleukin-2 Compounds of formulae I and I′, methods of making them, pharmaceutical compositions containing them, and methods for their use. The compounds are antagonists of IL-2/IL-2R binding; and are useful for the treatment of interleukin-2 mediated diseases, such as autoim...	10/19/2004
6784205	Compounds that modulate the activity of PTP-1B and TC-PTP The present invention relates to a new and improved method for treating diabetes and or its associated complications by modulating the activity of protein tryosin phosphatase 1B (“PTP-1B”). The inventive compounds modulate the activity PTP-1B by binding to a nov...	08/31/2004

PatentStorm

Famous Patents

PatentStorm News

Assignee: Sunesis Pharmaceuticals, Inc.